They’re non-invasive with none of the dreaded prep. But are recently approved home tests for colon cancer as effective as ...

Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are ...

2 “After having the same discussion year after year with my doctor, he mentioned that there are these Cologuard® box tests for colorectal cancer screening,” Leigh Anne said. “I was so ...

Because of their low sensitivity to adenomas, Shield and Cologuard both miss important opportunities to prevent cancer altogether. “A colonoscopy is both a diagnostic test and a therapeutic ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's ...

Reports preliminary FY24 revenue $2.76B, consensus $2.74B. Plans to launch three new cancer tests in 2025, namely Cologuard Plus, ...

Dr. Parul Shukla, a colon and rectal surgeon, told The Post that he always encourages his patients to commit to a colorectal ...

Exact Sciences Corporation EXAS is focused on further promoting Cologuard as the standard of care. The company prioritizes high-return pipeline opportunities with large patient impacts, which is ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael ...